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Supplementary Table 1. Baseline characteristics of participants by gender and body mass index category. 
  Body mass index, kg/m2    
  <18.5 18.5-24.9 25-29.9 ≥30 P trend  All 
Women         
No. of individuals (%)  976 (1.6%) 31,244 (52.3%) 18,646 (31.2%) 8,906 (14.9%)   59,772 (100%) 
Body mass index, kg/m2  17.9 (17.3-18.3) 22.5 (21.2-23.7) 26.9 (25.9-28.2) 32.7 (31.1-35.4)   24.6 (22.3-27.8) 
Age, years  54.0 (42.7-64.0) 53.4 (44.4-63.5) 58.9 (49.0-67.6) 59.2 (49.6-67.3) <0.001  56.0 (46.3-65.5) 
C-reactive protein, mg/L  1.1 (0.7-1.7) 1.3 (0.9-1.8) 1.6 (1.2-2.7) 2.6 (1.6-4.8) <0.001  1.5 (1.0-2.5) 
Current smokers  53% 73% 78% 79% <0.001  75% 
Smoking, pack-years (smokers only)  18 (10-30) 18 (9.6-30) 20 (10-32) 22 (11-35) <0.001  19 (10-30) 
Physical activity         
Low  58% 44% 47% 51% <0.001  46% 
Intermediate  36% 48% 46% 44% <0.001  47% 
High  7% 8% 6% 5% <0.001  7% 
Alcohol consumption, units per week  3 (0-8) 5 (2-10) 5 (2-10) 3 (1-8) <0.001  5 (2-10) 
Education         
Less than 10 years  23% 21% 31% 36% <0.001  26% 
10 to 13 years  45% 55% 51% 46% <0.001  52% 
13 years or more  16% 18% 13% 11% <0.001  15% 
Postmenopausal  62% 57% 70% 72% <0.001  63% 
         
         
Men         
No. of individuals (%)  182 (0.4%) 17,143 (35.0%) 23,595 (48.1%) 8,120 (16.6%)   49,040 (100%) 
Body mass index, kg/m2  17.9 (17.4-18.3) 23.4 (22.2-24.2) 27.1 (26.0-28.3) 32.0 (30.8-33.9)   26.2 (24.1-28.7) 
Age, years  54.0 (41.3-63.0) 54.0 (44.0-65.0) 57.8 (48.0-67.0) 58.9 (49.4-66.7) <0.001  56.7 (46.9-66.2) 
C-reactive protein, mg/L  1.3 (0.9-2.2) 1.2 (0.8-1.8) 1.5 (1.0-2.3) 2.0 (1.3-3.4) <0.001  1.4 (1.0-2.3) 
Current smokers  36% 66% 74% 76% <0.001  71% 
Smoking, pack-years (smokers only)  30 (20-41) 26 (15-40) 30 (16-44) 31 (18-48) <0.001  29 (15-43) 
Physical activity         
Low  70% 48% 45% 46% <0.001  46% 
Intermediate  23% 42% 44% 43% <0.001  43% 
High  8% 10% 11% 11% <0.001  10% 
Alcohol consumption, units per week  5.5 (0-16) 9 (4-18) 11 (4-20) 10 (3-20) <0.001  10 (4-19) 
Education         
Less than 10 years  19% 22% 29% 38% <0.001  28% 
10 to 13 years  32% 51% 49% 44% <0.001  49% 
13 years or more  20% 17% 15% 11% <0.001  15% 
 
Continuous values are median and interquartile range and categorical values are in percent. 1 unit alcohol=12g. 
 
Supplementary Figure 1. 
 
Distribution of body mass index in the general population (upper panel), the Copenhagen General 
Population Study and The Copenhagen City Heart Study, and the cumulative distribution function 
of body mass index (lower panel) showing the probability of a body mass index (y-axis) less than or 
equal to x as a function of number of body mass index elevating alleles. BMI=body mass index.
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Supplementary Figure 2. 
 
0.75 1 1.25 0.75 1 1.25 0 1 2 3 4 5 6 0 1 2 3 4 5 6 0 1 2 3 4 5 6
0 1 2 3 4 5 6 0 1 2 3 4 5 6 0 1 2 3 4 5 6 0 1 2 3 4 5 60 1 2 3 4 5 6
Potential confounder Observational BMI Allele score Any non-skin cancer Non-melanoma skin cancer Lung cancer 
  P value  P value  P value  P value  P value 
Age  <0.001  0.15  <0.001  <0.001  <0.001 
Gender  <0.001  0.29  <0.001  <0.001  <0.001 
CRP  <0.001  <0.001  <0.001  <0.001  0.21 
Smoking  <0.001  0.60  <0.001  <0.001  <0.001 
Physical activity  <0.001  0.30  <0.001  <0.001  <0.001 
Alcohol consumption  0.22  0.33  <0.001  <0.001  0.21 
Education  <0.001  0.22  <0.001  <0.001  <0.001 
Menopause (women)  <0.001  0.25  <0.001  <0.001  <0.001 
           
           
 Colon cancer Kidney cancer Breast cancer Prostate cancer Other cancers 
  P value  P value  P value  P value  P value 
Age  <0.001  <0.001  <0.001  <0.001  <0.001 
Gender  <0.001  <0.001  -  -  <0.001 
CRP  <0.001  <0.001  <0.001  <0.001  <0.001 
Smoking  <0.001  <0.001  0.35  <0.001  <0.001 
Physical activity  <0.001  <0.001  <0.001  <0.001  <0.001 
Alcohol consumption  0.38  0.48  <0.001  <0.001  <0.001 
Education  <0.001  <0.001  <0.001  <0.001  <0.001 
Menopause (women)  <0.001  <0.001  <0.001  -  <0.001 
Odds ratio (95% confidence interval)
Associations of potential confounders with body mass index, allele score, and cancer. Potential confounders were dichotomized: age (≥55 years versus 
<55 years), gender (men versus women), C-reactive protein concentrations (≥2mg/L versus <2mg/L), smoking (smoking versus non-smoking), 
physical activity (intermediate and high versus low), alcohol consumption (>14/21 versus ≤14/21 units per week for women/men), education (≥10 
years versus <10 years education), and for women menopausal status (postmenopausal versus premenopausal). For each potential confounder, logistic 
regression analysis was used to calculate age and gender-adjusted odds ratios and p-values for, respectively, a 1 kg/m2 increase in observational body 
mass index, a 1 unit increase in allele score, and for presence versus absence of cancer. BMI=body mass index, CRP=C-reactive protein.
Supplementary Figure 3A. 
 
  
Hazard/odds ratio for a 10kg/m
2
 higher BMI (95% CI)
0.1 0.5 1 2 4 8 16
 
 Participants Events  Hazard/odds ratio (95% CI) P value Power 
Any non-skin cancer   
All Observational 101.051 8,767  0.94 (0.89-0.99)  0.03  
 Genetic 97,458 11,248  1.16 (0.64-2.09)  0.62 1.54 
Women Observational 54,408 4,472  0.97 (0.90-1.04)  0.37  
 Genetic 53,499 6,376  0.83 (0.46-1.51)  0.55 1.78 
Men Observational 46,643 4,295  0.93 (0.86-1.02)  0.15  
 Genetic 43,958 4,872  4.10 (0.98-17)  0.05 1.93 
        
Non-melanoma skin cancer    
All Observational 102,809 3,420  0.63 (0.58-0.70)  <0.001  
 Genetic 97,458 7,406  0.71 (0.26-1.93)  0.51 1.68 
Women Observational 55,937 1,800  0.58 (0.52-0.66)  <0.001  
 Genetic 53,499 3,935  0.34 (0.12-0.99)  0.05 2.02 
Men Observational 46,872 1,620  0.74 (0.64-0.86)  <0.001  
 Genetic 43,958 3,470  1.26 (0.35-4.45)  0.72 2.13 
         
Lung cancer        
All Observational 106,930 1,567  0.64 (0.55-0.74)  <0.001  
 Genetic 97,458 896  1.32 (0.31-5.54)  0.71 4.09 
Women Observational 58,134 646  0.62 (0.50-0.76)  <0.001  
 Genetic 53,499 412  0.84 (0.13-5.42)  0.86 7.46 
Men Observational 48,796 921  0.68 (0.56-0.84)  <0.001  
 Genetic 43,958 484  1.43 (0.30-6.76)  0.65 6.64 
         
Other smoking related cancers (oral, larynx and bladder)    
All Observational 107,055 720  0.81 (0.66-1.00)  0.05  
 Genetic 97,458 761  1.18 (0.23-6.20)  0.84 4.43 
Women Observational 58,248 222  0.84 (0.60-1.18)  0.31  
 Genetic 53,499 208  0.47 (0.12-1.81)  0.27 17 
Men Observational 48,807 498  0.82 (0.63-1.06)  0.14  
 Genetic 43,958 553  1.97 (0.24-16)  0.52 5.73 
         
Colon cancer    
All Observational 106,392 1,330  1.05 (0.91-1.21)  0.53  
 Genetic 97,458 1,499  1.75 (0.47-6.58)  0.41 2.98 
Women Observational 57,878 667  0.97 (0.80-1.17)  0.72  
 Genetic 53,499 709  0.60 (0.21-1.71)  0.34 4.87 
Men Observational 48,514 663  1.17 (0.94-1.46)  0.17  
 Genetic 43,958 790  3.95 (0.81-19)  0.09 4.45 
Supplementary Figure 3B. 
 
 
Risk of cancer for a 10kg/m2 higher, respectively, observational and causal genetically determined 
body mass index in all participants, and women and men separately. The hazard ratio for a 10 kg/m2 
higher observational body mass index was calculated using Cox regression, while the odds ratio for 
genetically elevated body mass index was derived from an instrumental variable analysis. P-values 
Hazard/odds ratio for a 10kg/m
2
 higher BMI (95% CI)
0.1 0.5 1 2 4 8 16
 
 Participants Events  Hazard/odds ratio (95% CI) P value Power 
Kidney cancer       
All Observational 106,982 181  1.18 (0.80-1.74)  0.40  
 Genetic 97,458 193  1.00 (0.15-6.73)  0.99 19 
Women Observational 58,163 63  1.01 (0.55-1.85)  0.98  
 Genetic 53,499 66  0.22 (0.03-1.54)  0.13 281 
Men Observational 48,819 118  1.33 (0.80-2.21)  0.28  
 Genetic 43,958 125  1.17 (0.19-7.11)  0.86 37 
         
Breast cancer, premenopausal women      
Women Observational 21,500 497  0.90 (0.70-1.15)  0.39  
 Genetic 20,482 507  0.47 (0.14-1.51)  0.20 6.45 
        
Breast cancer, postmenopausal women      
Women Observational 34,836 973  1.14 (1.00-1.32)  0.06  
 Genetic 33,016 2,351  1.11 (0.34-3.59)  0.86 2.48 
        
Prostate cancer        
Men Observational 48,220 1,107  0.93 (0.78-1.10)  0.39  
 Genetic 43,958 1,576  2.46 (0.34-18)  0.37 2.47 
        
Other cancers      
All Observational 105,036 3,081  1.01 (0.93-1.11)  0.77  
 Genetic 97,458 4,216  3.95 (0.62-25)  0.15 1.94 
Women Observational 56,778 1,788  1.02 (0.92-1.14)  0.68  
 Genetic 53,809 2,530  2.67 (0.40-18)  0.31 2.37 
Men Observational 48,258 1,293  1.01 (0.86-1.18)  0.90  
 Genetic 44,172 1,686  0.80 (0.29-2.24)  0.67 2.85 
are, respectively, significance of hazard ratios and odds ratios. Power denotes the odds ratio that can 
be excluded at a two-sided α of 0.05 and ß of 80%.  
CI=confidence interval, BMI=body mass index.
Supplementary Figure 4. 
 
 
Risk of cancer for a 10kg/m2 higher, respectively, observational and causal genetically determined 
body mass index in participants. The odds ratio for genetically elevated body mass index was 
derived from an instrumental variable analysis using a weighted sum of risk alleles across the five 
Hazard/odds ratio for a 10kg/m
2
 higher BMI (95% CI)
0.1 0.5 1 2 4 8 16
 Participants Events  Hazard/odds ratio (95% CI) P value  
       
       
Any non-skin cancer   
 Observational 101,051 8,671  0.94 (0.89-0.99)  0.03  
 Genetic 97,458 11,248  1.15 (0.73-1.80)  0.55  
         
Non-melanoma skin cancer       
 Observational 102,809 3,420  0.63 (0.58-0.70)  <0.001  
 Genetic 97,458 7,406  0.94 (0.54-1.66)  0.84  
         
Lung cancer        
 Observational 106,930 1,567  0.64 (0.55-0.74)  <0.001  
 Genetic 97,458 896  1.62 (0.28-9.49)  0.59  
        
Other smoking related cancers (oral, larynx and bladder)    
 Observational 107,055 720  0.81 (0.66-1.00)  0.05  
 Genetic 97,458 761  1.59 (0.23-11)  0.64  
        
Colon cancer    
 Observational 106,392 1,330  1.05 (0.91-1.21)  0.53  
 Genetic 97,458 1,499  0.93 (0.24-3.58)  0.92  
        
Kidney cancer       
 Observational 106,982 181  1.18 (0.80-1.74)  0.40  
 Genetic 97,458 193  0.71 (0.005-93)  0.30  
        
Breast cancer, premenopausal women      
 Observational 21,500 497  0.90 (0.70-1.15)  0.39  
 Genetic 20,482 507  0.20 (0.02-2.04)  0.17  
         
Breast cancer, postmenopausal women      
 Observational 34,836 973  1.14 (1.00-1.32)  0.06  
 Genetic 33,016 2,351  0.93 (0.86-1.00)  0.06  
         
Prostate cancer, men        
 Observational 48,220 1,107  0.93 (0.78-1.10)  0.39  
 Genetic 43,958 1,576  2.28 (0.59-8.89)  0.23  
         
Other cancers       
 Observational 105,036 3,081  1.01 (0.93-1.11)  0.77  
 Genetic 97,458 4,216  1.79 (0.83-3.86)  0.14  
    
    
         
         
        
      
         
         
         
    
         
         
 
genotypes applying a weight equal to the effect of each variant on body mass index reported by a 
previous genome wide association study[1]. The hazard ratio for a 10 kg/m2 higher observational 
body mass index was calculated using Cox regression. P-values are, respectively, significance of 
hazard ratios and odds ratios. CI=confidence interval, BMI=body mass index.
Supplementary Figure 5. 
 
 
Risk of cancer for a 10kg/m2 higher, respectively, observational and causal genetically determined 
body mass index in participants. The odds ratio for genetically elevated body mass index was 
estimated using an allele score combining the FTO(rs9939609), MC4R(rs17782313), 
Hazard/odds ratio for a 10kg/m
2
 higher BMI (95% CI)
0.1 0.5 1 2 4 8 16
 Participants Events  Hazard/odds ratio (95% CI) P value  
       
       
Any non-skin cancer   
 Observational 101,051 8,671  0.94 (0.89-0.99)  0.03  
 Genetic 97,458 11,248  1.19 (0.64-2.22)  0.58  
         
Non-melanoma skin cancer       
 Observational 102,809 3,420  0.63 (0.58-0.70)  <0.001  
 Genetic 97,458 7,406  0.98 (0.29-3.37)  0.98  
         
Lung cancer        
 Observational 106,930 1,567  0.64 (0.55-0.74)  <0.001  
 Genetic 97,458 896  1.31 (0.20-8.62)  0.78  
        
Other smoking related cancers (oral, larynx and bladder)    
 Observational 107,055 720  0.81 (0.66-1.00)  0.05  
 Genetic 97,458 761  1.88 (0.20-18)  0.59  
        
Colon cancer    
 Observational 106,392 1,330  1.05 (0.91-1.21)  0.53  
 Genetic 97,458 1,499  0.90 (0.32-2.51)  0.85  
        
Kidney cancer       
 Observational 106,982 181  1.18 (0.80-1.74)  0.40  
 Genetic 97,458 193  0.70 (0.14-3.58)  0.67  
        
Breast cancer, premenopausal women      
 Observational 21,500 497  0.90 (0.70-1.15)  0.39  
 Genetic 20,482 507  0.51 (0.10-2.52)  0.41  
         
Breast cancer, postmenopausal women      
 Observational 34,836 973  1.14 (1.00-1.32)  0.06  
 Genetic 33,016 2,351  0.51 (0.31-0.85)  0.009  
         
Prostate cancer, men        
 Observational 48,220 1,107  0.93 (0.78-1.10)  0.39  
 Genetic 43,958 1,576  1.40 (0.31-6.27)  0.66  
         
Other cancers       
 Observational 105,036 3,081  1.01 (0.93-1.11)  0.77  
 Genetic 97,458 4,216  2.48 (0.68-9.03)  0.17  
    
    
         
         
        
      
         
         
         
    
         
         
 
TMEM18(rs6548238), and GNPDA2(rs10938397) genotypes and thus omitting the 
BDNF(rs10767664) genotype. This was done as a sensitivity analysis, since it has been suggested 
that this genotype may have a pleiotropic effect on smoking so that the allele associated with a high 
body mass index is associated with a higher propensity for smoking. The hazard ratio for a 10 kg/m2 
higher observational body mass index was calculated using Cox regression. P-values are, 
respectively, significance of hazard ratios and odds ratios. CI=confidence interval, BMI=body mass 
index.
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